Hairy-cell leukemia (HCL) is a rare, indolent neoplasm of mature B cells with hairlike surface projections that circulate in the blood and preferentially infiltrate the bone marrow and spleen. The ...

Hairy cell leukaemia (HCL) remains an intriguing B‐cell malignancy defined by its distinctive “hairy” cytoplasmic projections and its unique pattern of bone marrow infiltration. Recent research has ...

The Hairy Cell Leukemia Foundation will host a free patient forum on July 17th with guest speaker Dr. Martin Tallman from Memorial Sloan Kettering Cancer Center. This forum is free and open to the ...

Use of the BRAF inhibitor vemurafenib (Zelboraf) combined with the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) led to high rates of complete remission as frontline therapy for patients with ...

Phase II Trial of Autologous Tumor Vaccination, Anti-CD3-Activated Vaccine-Primed Lymphocytes, and Interleukin-2 in Stage IV Renal Cell Cancer Purpose: Hairy cell leukemia (HCL) is an uncommon, ...

Venetoclax (Venclexta) shows promise as salvage therapy for patients with relapsed or refractory hairy cell leukemia (HCL), according to a small study in which five of six patients responded to the ...

HCL uniformly harbors a BRAF mutation that is not present in other B-cell malignancies. Hairy cell leukemia (HCL) is an indolent B-cell lymphoproliferative disorder that responds to several highly ...

Another fundamental feature of hairy-cell leukemia is the overexpression of the antiapoptotic protein BCL2. 4 BCL2 levels in patients with hairy-cell leukemia are as high as those seen in patients ...

Long-term follow-up of patients with hairy cell leukemia treated with different modalities at a single institution: Real-life experience over 25 years. This is an ASCO Meeting Abstract from the 2024 ...